Carisma Therapeutics INC 8-K filings

Carisma Therapeutics Inc. announced its voluntary delisting from Nasdaq, executive and board changes, and plans to terminate SEC reporting obligations as it proceeds with wind-down activities.

Carisma Therapeutics Inc. announced the termination of its CEO and CSO, along with multiple board resignations, as it pursues an orderly wind-down of operations.

Carisma Therapeutics Inc. received a delisting notice from Nasdaq, with trading to cease on October 13, 2025, and plans to move to the OTCID market tier while pursuing an orderly wind-down.

Carisma Therapeutics Inc. terminated its merger agreement with OrthoCellix due to failed financing and amended its collaboration with Moderna for a one-time payment.

Carisma Therapeutics Inc. announced a $5 million private placement with Ocugen, an extension for Nasdaq listing compliance, and an amended employment agreement for its CEO, all tied to its pending merger with OrthoCellix.

Carisma Therapeutics Inc. stockholders approved a reverse stock split proposal at a Special Meeting, granting the Board discretion on the ratio and timing, alongside discussions of a proposed merger with OrthoCellix Inc.

Carisma Therapeutics Inc. received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement and is planning a reverse stock split and a merger with OrthoCellix, Inc. to regain compliance.

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement to combine, creating a publicly-traded company focused on regenerative cell therapies for orthopedic diseases, with existing Carisma stockholders receiving contingent value rights.

Carisma Therapeutics Inc. has received a conditional extension from Nasdaq to maintain its listing, transferring to The Nasdaq Capital Market while facing strict compliance deadlines for bid price and market value.

Carisma Therapeutics is at risk of being delisted from the Nasdaq due to its failure to meet minimum market value and share price requirements.

Carisma Therapeutics plans to initiate a Phase 1 clinical trial of CT-1119 in combination with tislelizumab for solid tumors and advance its liver fibrosis program.

Carisma Therapeutics Inc. has received a notification from Nasdaq that it is not in compliance with the minimum bid price requirement of $1.00 per share.

Carisma Therapeutics has appointed Natalie McAndrew as interim Vice President of Finance, effective January 1, 2025, while also engaging Danforth Global for finance and accounting services.

Carisma Therapeutics is reducing its workforce by 34% and halting development of its lead product candidate, CT-0525, to focus on other programs.

Carisma Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical and preclinical programs, including upcoming data presentations and development candidate nominations.

Carisma Therapeutics has announced the resignation of Michael Torok from its board of directors and the appointment of Sohanya Cheng as a new director, effective October 31, 2024.

Carisma Therapeutics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting the company at risk of potential delisting.

Carisma Therapeutics announced its second quarter 2024 financial results and provided updates on its clinical trials, including initial data for its lead anti-HER2 product candidate expected by year-end.

Carisma Therapeutics reports that 75% of HER2 3+ cancer patients in a Phase 1 trial experienced a reduction in circulating tumor DNA (ctDNA) after treatment with CT-0508.

Carisma Therapeutics has terminated its manufacturing agreement with Novartis for CT-0508, incurring a $4 million fee, as it pivots to focus on its next product candidate, CT-0525.

Carisma Therapeutics has appointed two new directors, Marella Thorell and David Scadden, effective June 30, 2024, following the resignations of Regina Hodits and Bjrn Odlander.

Carisma Therapeutics has announced the nomination of its first development candidate under its collaboration with Moderna, triggering a $2 million milestone payment.

Carisma Therapeutics successfully held its reconvened annual meeting on June 14, 2024, electing directors and ratifying the appointment of its auditor after an initial meeting was adjourned due to technical issues.

Carisma Therapeutics has granted stock options to its named executive officers as a retention incentive during the implementation of its revised operating plan.

Carisma Therapeutics announced its first quarter 2024 financial results, highlighted the prioritization of its CT-0525 program, and provided updates on its clinical and preclinical programs.

Carisma Therapeutics reported encouraging preliminary results from its Phase 1 clinical trial of CT-0508, both as a monotherapy and in combination with pembrolizumab, for treating HER2 overexpressing cancers.

Carisma Therapeutics is prioritizing its CT-0525 program, pausing development of CT-1119, and restructuring operations, including a 37% workforce reduction, to extend its cash runway into the third quarter of 2025.